Discovery and development of substituted tyrosine derivatives as Bcl-2/Mcl-1 inhibitors

Add time:07/17/2019    Source:sciencedirect.com

Anti-apoptotic Bcl-2 family proteins are vital for cancer cells to escape apoptosis, which make them attractive targets for cancer therapy. Recently, a lead compound 1 was found to modestly inhibit the binding of BH3 peptide to Bcl-2 protein with a Ki value of 5.2 µM. Based on this, a series of substituted tyrosine derivatives were developed and tested for their binding affinities to Bcl-2 protein. Results indicated that these compounds exhibited potent binding affinities to Bcl-2 and Mcl-1 protein but not to Bcl-XL protein. Promisingly, compound 6i inhibited the binding of BH3 peptide to Bcl-2 and Mcl-1 protein with a Ki value of 450 and 190 nM respectively, and showed obvious anti-proliferative activities against tested cancer cells.

We also recommend Trading Suppliers and Manufacturers of 1-(2-BUTYL)-4-(2-CHLORO-ETHYL)-PIPERAZINE X 2 HCL (cas 722491-43-2). Pls Click Website Link as below: cas 722491-43-2 suppliers

Prev:Reaction of 2-hetarylacetonitriles with ethyl 2-alkylsulfanyl-4-chloro-5-pyrimidinecarboxylates. Synthesis of new condensed pyrimidines
Next:Synthesis and evaluation of novel 2-butyl-4-chloro-1-methylimidazole embedded chalcones and pyrazoles as angiotensin converting enzyme (ACE) inhibitors)